MedTrace Logo

Use of Corifolitropin Alfa in Oocyte Donors

NCT02213627 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2015-07-17

No results posted yet for this study

Summary

The purpose of this study is to determine if corifollitropin alfa (long-term gonadotropin administration) is effective in a controlled ovarian stimulation protocol in oocyte donors compared to daily gonadotropin administration (recombinant FSH or HP-hMG)

Conditions

Interventions

DRUG

Corifollitropin alfa

DRUG

Recombinant FSH

DRUG

HP-hMG

Sponsors & Collaborators

  • Instituto Valenciano de Infertilidad, IVI VALENCIA

    collaborator OTHER

  • Instituto Valenciano de Infertilidad, IVI Alicante

    collaborator OTHER

  • IVI Madrid

    lead OTHER

Principal Investigators

  • Antonio Requena, MD, PhD · IVI Madrid

  • Manuel Muñoz, MD, PhD · Instituto Valenciano de Infertilidad, IVI Alicante

  • Pilar Alamá, MD, PhD · IVI Valencia

  • María Cruz, PhD · IVI Madrid

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-09-30
Completion
2015-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02213627 on ClinicalTrials.gov